-
1
-
-
0036792124
-
Pegylated arginine deiminase (ADI-SS PEG20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo
-
Ensor CM, Holtsberg FW, Bomalaski JS and Clark MA. Pegylated arginine deiminase (ADI-SS PEG20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002; 62:5443-5450.
-
(2002)
Cancer Res
, vol.62
, pp. 5443-5450
-
-
Ensor, C.M.1
Holtsberg, F.W.2
Bomalaski, J.S.3
Clark, M.A.4
-
2
-
-
8344258040
-
Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents
-
Wheatley DN. Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs. 2004; 15:825-833.
-
(2004)
Anticancer Drugs
, vol.15
, pp. 825-833
-
-
Wheatley, D.N.1
-
3
-
-
0029124788
-
Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism
-
Takaku H, Matsumoto M, Misawa S and Miyazaki K. Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism. Jpn J Cancer Res. 1995; 86:840-846.
-
(1995)
Jpn J Cancer Res
, vol.86
, pp. 840-846
-
-
Takaku, H.1
Matsumoto, M.2
Misawa, S.3
Miyazaki, K.4
-
4
-
-
0026686536
-
High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro
-
Sugimura K, Ohno T, Kusuyama T and Azuma I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res. 1992; 2:191-196.
-
(1992)
Melanoma Res
, vol.2
, pp. 191-196
-
-
Sugimura, K.1
Ohno, T.2
Kusuyama, T.3
Azuma, I.4
-
5
-
-
45549107064
-
Arginine deprivation as a targeted therapy for cancer
-
Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S and Savaraj N. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des. 2008; 14:1049-1057.
-
(2008)
Curr Pharm Des
, vol.14
, pp. 1049-1057
-
-
Feun, L.1
You, M.2
Wu, C.J.3
Kuo, M.T.4
Wangpaichitr, M.5
Spector, S.6
Savaraj, N.7
-
6
-
-
84860251804
-
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
-
Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer. 2012; 106:1481-1485.
-
(2012)
Br J Cancer
, vol.106
, pp. 1481-1485
-
-
Feun, L.G.1
Marini, A.2
Walker, G.3
Elgart, G.4
Moffat, F.5
Rodgers, S.E.6
Wu, C.J.7
You, M.8
Wangpaichitr, M.9
Kuo, M.T.10
Sisson, W.11
Jungbluth, A.A.12
Bomalaski, J.13
-
7
-
-
32944469353
-
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies
-
Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol. 2005; 23:7660-7668.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7660-7668
-
-
Ascierto, P.A.1
Scala, S.2
Castello, G.3
Daponte, A.4
Simeone, E.5
Ottaiano, A.6
Beneduce, G.7
De Rosa, V.8
Izzo, F.9
Melucci, M.T.10
Ensor, C.M.11
Prestayko, A.W.12
Holtsberg, F.W.13
-
8
-
-
33747181970
-
Pegylated arginine deiminase: a novel anticancer enzyme agent
-
Feun L and Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006; 15:815-822.
-
(2006)
Expert Opin Investig Drugs
, vol.15
, pp. 815-822
-
-
Feun, L.1
Savaraj, N.2
-
9
-
-
77953491512
-
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma
-
Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT and Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med. 2010; 10:405-412.
-
(2010)
Curr Mol Med
, vol.10
, pp. 405-412
-
-
Savaraj, N.1
You, M.2
Wu, C.3
Wangpaichitr, M.4
Kuo, M.T.5
Feun, L.G.6
-
10
-
-
58349098150
-
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis
-
Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FY, Bold RJ and Kung HJ. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 2009; 69:700-708.
-
(2009)
Cancer Res
, vol.69
, pp. 700-708
-
-
Kim, R.H.1
Coates, J.M.2
Bowles, T.L.3
McNerney, G.P.4
Sutcliffe, J.5
Jung, J.U.6
Gandour-Edwards, R.7
Chuang, F.Y.8
Bold, R.J.9
Kung, H.J.10
-
11
-
-
47249136177
-
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma
-
Savaraj N, Wu C, Kuo M, You M, Wangpaichitr M, Robles C, Sepector S and Feun L. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights. 2007; 2:119-128.
-
(2007)
Drug Target Insights
, vol.2
, pp. 119-128
-
-
Savaraj, N.1
Wu, C.2
Kuo, M.3
You, M.4
Wangpaichitr, M.5
Robles, C.6
Sepector, S.7
Feun, L.8
-
12
-
-
79954473064
-
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells
-
Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, Gentilcore G, Capone M, Mozzillo N, Rozzo C, Cossu A, Tanda F and Palmieri G. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep. 25:1495-1502.
-
Oncol Rep
, vol.25
, pp. 1495-1502
-
-
Manca, A.1
Sini, M.C.2
Izzo, F.3
Ascierto, P.A.4
Tatangelo, F.5
Botti, G.6
Gentilcore, G.7
Capone, M.8
Mozzillo, N.9
Rozzo, C.10
Cossu, A.11
Tanda, F.12
Palmieri, G.13
-
13
-
-
77950501356
-
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines
-
You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM and Feun L. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun. 2010; 394:760-766.
-
(2010)
Biochem Biophys Res Commun
, vol.394
, pp. 760-766
-
-
You, M.1
Savaraj, N.2
Wangpaichitr, M.3
Wu, C.4
Kuo, M.T.5
Varona-Santos, J.6
Nguyen, D.M.7
Feun, L.8
-
14
-
-
84872005452
-
TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation
-
You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM and Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem. 2013; 374:181-190.
-
(2013)
Mol Cell Biochem
, vol.374
, pp. 181-190
-
-
You, M.1
Savaraj, N.2
Kuo, M.T.3
Wangpaichitr, M.4
Varona-Santos, J.5
Wu, C.6
Nguyen, D.M.7
Feun, L.8
-
15
-
-
79956144655
-
Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1
-
Li H, Wang P, Sun Q, Ding WX, Yin XM, Sobol RW, Stolz DB, Yu J and Zhang L. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Res. 71:3625-3634.
-
Cancer Res
, vol.71
, pp. 3625-3634
-
-
Li, H.1
Wang, P.2
Sun, Q.3
Ding, W.X.4
Yin, X.M.5
Sobol, R.W.6
Stolz, D.B.7
Yu, J.8
Zhang, L.9
-
16
-
-
0345256652
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance
-
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22:7265-7279.
-
(2003)
Oncogene
, vol.22
, pp. 7265-7279
-
-
Siddik, Z.H.1
-
17
-
-
39749166975
-
DNA repair pathways as targets for cancer therapy
-
Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8:193-204.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 193-204
-
-
Helleday, T.1
Petermann, E.2
Lundin, C.3
Hodgson, B.4
Sharma, R.A.5
-
18
-
-
36749022214
-
The DNA damage response: ten years after
-
Harper JW and Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007; 28:739-745.
-
(2007)
Mol Cell
, vol.28
, pp. 739-745
-
-
Harper, J.W.1
Elledge, S.J.2
-
19
-
-
84873388790
-
gamma-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000)
-
Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D and Hartley JA. gamma-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res. 2013; 19:721-730.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 721-730
-
-
Wu, J.1
Clingen, P.H.2
Spanswick, V.J.3
Mellinas-Gomez, M.4
Meyer, T.5
Puzanov, I.6
Jodrell, D.7
Hochhauser, D.8
Hartley, J.A.9
-
20
-
-
14644399209
-
FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy
-
Ferrer M, Span SW, Vischioni B, Oudejans JJ, van Diest PJ, de Winter JP, Giaccone G and Kruyt FA. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. Clin Lung Cancer. 2005; 6:250-254.
-
(2005)
Clin Lung Cancer
, vol.6
, pp. 250-254
-
-
Ferrer, M.1
Span, S.W.2
Vischioni, B.3
Oudejans, J.J.4
van Diest, P.J.5
de Winter, J.P.6
Giaccone, G.7
Kruyt, F.A.8
-
21
-
-
64549109258
-
A role for monoubiquitinated FANCD2 at telomeres in ALT cells
-
Fan Q, Zhang F, Barrett B, Ren K and Andreassen PR. A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res. 2009; 37:1740-1754.
-
(2009)
Nucleic Acids Res
, vol.37
, pp. 1740-1754
-
-
Fan, Q.1
Zhang, F.2
Barrett, B.3
Ren, K.4
Andreassen, P.R.5
-
22
-
-
4043133287
-
ATR couples FANCD2 monoubiquitination to the DNA-damage response
-
Andreassen PR, D'Andrea AD and Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 2004; 18:1958-1963.
-
(2004)
Genes Dev
, vol.18
, pp. 1958-1963
-
-
Andreassen, P.R.1
D'Andrea, A.D.2
Taniguchi, T.3
-
23
-
-
67650569540
-
Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M
-
Singh TR, Bakker ST, Agarwal S, Jansen M, Grassman E, Godthelp BC, Ali AM, Du CH, Rooimans MA, Fan Q, Wahengbam K, Steltenpool J, Andreassen PR, et al. Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. Blood. 2009; 114:174-180.
-
(2009)
Blood
, vol.114
, pp. 174-180
-
-
Singh, T.R.1
Bakker, S.T.2
Agarwal, S.3
Jansen, M.4
Grassman, E.5
Godthelp, B.C.6
Ali, A.M.7
Du, C.H.8
Rooimans, M.A.9
Fan, Q.10
Wahengbam, K.11
Steltenpool, J.12
Andreassen, P.R.13
-
24
-
-
27744432361
-
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation
-
Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wust AP, Yousefi S, Simon HU, Stahel R and Zangemeister-Wittke U. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer. 2005; 117:755-763.
-
(2005)
Int J Cancer
, vol.117
, pp. 755-763
-
-
Belyanskaya, L.L.1
Hopkins-Donaldson, S.2
Kurtz, S.3
Simoes-Wust, A.P.4
Yousefi, S.5
Simon, H.U.6
Stahel, R.7
Zangemeister-Wittke, U.8
-
25
-
-
84877104834
-
Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells
-
Ding ZY, Liu GH, Olsson B and Sun XF. Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells. Tumour Biol. 2013; 34:683-693.
-
(2013)
Tumour Biol
, vol.34
, pp. 683-693
-
-
Ding, Z.Y.1
Liu, G.H.2
Olsson, B.3
Sun, X.F.4
-
26
-
-
68149153007
-
Noxa: at the tip of the balance between life and death
-
Ploner C, Kofler R and Villunger A. Noxa: at the tip of the balance between life and death. Oncogene. 2008; 27 Suppl 1:S84-92.
-
(2008)
Oncogene
, vol.27
, pp. S84-S92
-
-
Ploner, C.1
Kofler, R.2
Villunger, A.3
-
27
-
-
48649102539
-
The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways
-
Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, Tannapfel A, Gulbins E, Schulze-Osthoff K and Hengge UR. The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene. 2008; 27:4557-4568.
-
(2008)
Oncogene
, vol.27
, pp. 4557-4568
-
-
Hassan, M.1
Alaoui, A.2
Feyen, O.3
Mirmohammadsadegh, A.4
Essmann, F.5
Tannapfel, A.6
Gulbins, E.7
Schulze-Osthoff, K.8
Hengge, U.R.9
-
28
-
-
84873524063
-
Anti-apoptotic proteins on guard of melanoma cell survival
-
Hartman ML and Czyz M. Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett. 331:24-34.
-
Cancer Lett
, vol.331
, pp. 24-34
-
-
Hartman, M.L.1
Czyz, M.2
-
29
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380:358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
Rutkowski, P.7
Blank, C.U.8
Miller, W.H.9
Kaempgen, E.10
Martin-Algarra, S.11
Karaszewska, B.12
Mauch, C.13
-
30
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468:973-977.
-
(2010)
Nature
, vol.468
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
Kong, X.4
Koya, R.C.5
Lee, H.6
Chen, Z.7
Lee, M.K.8
Attar, N.9
Sazegar, H.10
Chodon, T.11
Nelson, S.F.12
McArthur, G.13
-
31
-
-
84868120907
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
-
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13:1087-1095.
-
(2012)
Lancet Oncol
, vol.13
, pp. 1087-1095
-
-
Long, G.V.1
Trefzer, U.2
Davies, M.A.3
Kefford, R.F.4
Ascierto, P.A.5
Chapman, P.B.6
Puzanov, I.7
Hauschild, A.8
Robert, C.9
Algazi, A.10
Mortier, L.11
Tawbi, H.12
Wilhelm, T.13
-
32
-
-
84875706825
-
Resistance to BRAF-targeted therapy in melanoma
-
Sullivan RJ and Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013; 49:1297-1304.
-
(2013)
Eur J Cancer
, vol.49
, pp. 1297-1304
-
-
Sullivan, R.J.1
Flaherty, K.T.2
-
33
-
-
84884901558
-
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
-
Menzies AM and Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer. 2013; 49:3229-3241.
-
(2013)
Eur J Cancer
, vol.49
, pp. 3229-3241
-
-
Menzies, A.M.1
Long, G.V.2
-
34
-
-
84872695626
-
Emerging therapies in melanoma
-
Wolchok JD. Emerging therapies in melanoma. Clin Adv Hematol Oncol. 2012; 10:742-743.
-
(2012)
Clin Adv Hematol Oncol
, vol.10
, pp. 742-743
-
-
Wolchok, J.D.1
-
35
-
-
84916880046
-
In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts
-
Agrawal V, Woo JH, Mauldin JP, Stone EM, Meininger CJ, Jo C, Kleypas K, Frenkel EP and Frankel AE. In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts. Melanoma Res. 2014; 24:556-567.
-
(2014)
Melanoma Res
, vol.24
, pp. 556-567
-
-
Agrawal, V.1
Woo, J.H.2
Mauldin, J.P.3
Stone, E.M.4
Meininger, C.J.5
Jo, C.6
Kleypas, K.7
Frenkel, E.P.8
Frankel, A.E.9
-
36
-
-
79952598775
-
Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis
-
Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, Cheng PN, Wheatley DN, Lo WH and Leung YC. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 2011; 24:366-376.
-
(2011)
Pigment Cell Melanoma Res
, vol.24
, pp. 366-376
-
-
Lam, T.L.1
Wong, G.K.2
Chow, H.Y.3
Chong, H.C.4
Chow, T.L.5
Kwok, S.Y.6
Cheng, P.N.7
Wheatley, D.N.8
Lo, W.H.9
Leung, Y.C.10
-
37
-
-
77950003784
-
Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines
-
Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL and Georgiou G. Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. ACS Chem Biol. 2010; 5:333-342.
-
(2010)
ACS Chem Biol
, vol.5
, pp. 333-342
-
-
Stone, E.M.1
Glazer, E.S.2
Chantranupong, L.3
Cherukuri, P.4
Breece, R.M.5
Tierney, D.L.6
Curley, S.A.7
Iverson, B.L.8
Georgiou, G.9
-
38
-
-
65649127785
-
Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)
-
Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY, Arnold S, Cheng PN, Wheatley DN, Lo WH and Leung YC. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int. 2009; 9:9.
-
(2009)
Cancer Cell Int
, vol.9
, pp. 9
-
-
Tsui, S.M.1
Lam, W.M.2
Lam, T.L.3
Chong, H.C.4
So, P.K.5
Kwok, S.Y.6
Arnold, S.7
Cheng, P.N.8
Wheatley, D.N.9
Lo, W.H.10
Leung, Y.C.11
-
39
-
-
84866912486
-
Fanconi anemia proteins FANCD2 and FANCI exhibit different DNA damage responses during S-phase
-
Sareen A, Chaudhury I, Adams N and Sobeck A. Fanconi anemia proteins FANCD2 and FANCI exhibit different DNA damage responses during S-phase. Nucleic Acids Res. 2012; 40:8425-8439.
-
(2012)
Nucleic Acids Res
, vol.40
, pp. 8425-8439
-
-
Sareen, A.1
Chaudhury, I.2
Adams, N.3
Sobeck, A.4
-
40
-
-
38449103060
-
The Fanconi anemia pathway and ubiquitin
-
Jacquemont C and Taniguchi T. The Fanconi anemia pathway and ubiquitin. BMC Biochem. 2007; 8 Suppl 1:S10.
-
(2007)
BMC Biochem
, vol.8
, pp. S10
-
-
Jacquemont, C.1
Taniguchi, T.2
-
41
-
-
33646582299
-
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
-
Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV and D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006; 5:952-961.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 952-961
-
-
Chirnomas, D.1
Taniguchi, T.2
de la Vega, M.3
Vaidya, A.P.4
Vasserman, M.5
Hartman, A.R.6
Kennedy, R.7
Foster, R.8
Mahoney, J.9
Seiden, M.V.10
D'Andrea, A.D.11
-
42
-
-
84878551066
-
Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks
-
Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q and Houghton PJ. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res. 2013; 73:3393-3401.
-
(2013)
Cancer Res
, vol.73
, pp. 3393-3401
-
-
Shen, C.1
Oswald, D.2
Phelps, D.3
Cam, H.4
Pelloski, C.E.5
Pang, Q.6
Houghton, P.J.7
-
43
-
-
34249947699
-
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
-
Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP and Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007; 316:1160-1166.
-
(2007)
Science
, vol.316
, pp. 1160-1166
-
-
Matsuoka, S.1
Ballif, B.A.2
Smogorzewska, A.3
McDonald, E.R.4
Hurov, K.E.5
Luo, J.6
Bakalarski, C.E.7
Zhao, Z.8
Solimini, N.9
Lerenthal, Y.10
Shiloh, Y.11
Gygi, S.P.12
Elledge, S.J.13
-
44
-
-
26844545448
-
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
-
Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T and Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer. 2005; 4:25.
-
(2005)
Mol Cancer
, vol.4
, pp. 25
-
-
Wu, C.1
Wangpaichitr, M.2
Feun, L.3
Kuo, M.T.4
Robles, C.5
Lampidis, T.6
Savaraj, N.7
-
45
-
-
84873524063
-
Anti-apoptotic proteins on guard of melanoma cell survival
-
Hartman ML and Czyz M. Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett. 2013; 331:24-34.
-
(2013)
Cancer Lett
, vol.331
, pp. 24-34
-
-
Hartman, M.L.1
Czyz, M.2
-
46
-
-
0036566426
-
Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin
-
Thomas JB, Holtsberg FW, Ensor CM, Bomalaski JS and Clark MA. Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin. Biochem J. 2002; 363:581-587.
-
(2002)
Biochem J
, vol.363
, pp. 581-587
-
-
Thomas, J.B.1
Holtsberg, F.W.2
Ensor, C.M.3
Bomalaski, J.S.4
Clark, M.A.5
-
47
-
-
0036652959
-
Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production
-
Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS and Clark MA. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med Sci Monit. 2002; 8:BR248-253.
-
(2002)
Med Sci Monit
, vol.8
, pp. BR248-BR253
-
-
Dillon, B.J.1
Holtsberg, F.W.2
Ensor, C.M.3
Bomalaski, J.S.4
Clark, M.A.5
-
48
-
-
33845635205
-
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis
-
Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol. 2007; 22:86-91.
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 86-91
-
-
Izzo, F.1
Montella, M.2
Orlando, A.P.3
Nasti, G.4
Beneduce, G.5
Castello, G.6
Cremona, F.7
Ensor, C.M.8
Holtzberg, F.W.9
Bomalaski, J.S.10
Clark, M.A.11
Curley, S.A.12
Orlando, R.13
-
49
-
-
0345791531
-
Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines
-
Tang CH and Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem. 2004; 279:288-298.
-
(2004)
J Biol Chem
, vol.279
, pp. 288-298
-
-
Tang, C.H.1
Grimm, E.A.2
-
50
-
-
77949712411
-
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy
-
Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA and Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010; 16:1834-1844.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1834-1844
-
-
Sikora, A.G.1
Gelbard, A.2
Davies, M.A.3
Sano, D.4
Ekmekcioglu, S.5
Kwon, J.6
Hailemichael, Y.7
Jayaraman, P.8
Myers, J.N.9
Grimm, E.A.10
Overwijk, W.W.11
-
51
-
-
84870877479
-
Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin
-
Godoy LC, Anderson CT, Chowdhury R, Trudel LJ and Wogan GN. Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci USA. 109:20373-20378.
-
Proc Natl Acad Sci USA
, vol.109
, pp. 20373-20378
-
-
Godoy, L.C.1
Anderson, C.T.2
Chowdhury, R.3
Trudel, L.J.4
Wogan, G.N.5
-
52
-
-
84891421503
-
Acquired resistance to chemotherapy in lung cancer cells mediated by prolonged nitric oxide exposure
-
Wongvaranon P, Pongrakhananon V, Chunhacha P and Chanvorachote P. Acquired resistance to chemotherapy in lung cancer cells mediated by prolonged nitric oxide exposure. Anticancer Res. 33:5433-5444.
-
Anticancer Res
, vol.33
, pp. 5433-5444
-
-
Wongvaranon, P.1
Pongrakhananon, V.2
Chunhacha, P.3
Chanvorachote, P.4
-
54
-
-
85039892512
-
Potentiation of antitumor effect of DNA damaging agents by ADI in melanoma
-
Feun L, Wu C, Lee S, Kuo M, Wangpaichitr M, Robles C and Savaraj N. Potentiation of antitumor effect of DNA damaging agents by ADI in melanoma. Proc Am Assoc Can Res. 2007; 48.
-
(2007)
Proc Am Assoc Can Res
, vol.48
-
-
Feun, L.1
Wu, C.2
Lee, S.3
Kuo, M.4
Wangpaichitr, M.5
Robles, C.6
Savaraj, N.7
-
55
-
-
84887483618
-
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction
-
Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG and Kuo MT. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther. 2013; 12:2581-2590.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 2581-2590
-
-
Long, Y.1
Tsai, W.B.2
Wangpaichitr, M.3
Tsukamoto, T.4
Savaraj, N.5
Feun, L.G.6
Kuo, M.T.7
|